Denosumab Market 2026 benefiting from advancements in bone health therapies

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Denosumab Market At The End Of The 2026–2030 Forecast Period?

The denosumab market size has experienced rapid growth in recent years. It is anticipated to expand from $3.67 billion in 2025 to $4.06 billion in 2026, at a compound annual growth rate (CAGR) of 10.7%. The expansion observed in the historic period can be linked to the high prevalence of osteoporosis and bone-related disorders, a growing geriatric population, early approvals of denosumab therapies, increasing hospital and specialty clinic capacities, and rising awareness of fracture risk among patients.

The denosumab market is projected for significant expansion over the coming years, reaching $6.06 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.5%. This anticipated growth during the forecast period stems from several factors, including developments in precision medicine and biologics, the broadening of homecare and ambulatory services, greater investment in bone health research, the introduction of advanced denosumab formulations, and increasing demand across developing markets. Key trends expected to shape this period encompass a rise in the use of monoclonal antibodies, the expansion of osteoporosis screening initiatives, tailored treatment strategies for bone metastases, an increase in home-based injection therapies, and heightened awareness of bone health among the elderly population.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp

Which Market Drivers Are Supporting The Expansion Of The Denosumab Market?

The rising prevalence of osteoporosis is anticipated to drive the expansion of the denosumab market. Osteoporosis is a health condition characterized by weakened bones, diminished bone density, and an increased susceptibility to fractures. Denosumab addresses osteoporosis by hindering bone resorption via targeting the RANK ligand. For example, in September 2023, data from the Canadian Longitudinal Study on Aging, cited by the US-based National Center for Biotechnology Information, showed that among community-dwelling older adult females, the prevalence of physician-diagnosed osteoporosis was 12.7%, and DXA-confirmed osteoporosis was 5.9%. Moreover, a cross-sectional study by Buttros and colleagues reported a 24.6% prevalence of osteoporosis in postmenopausal women between 40 and 75 years old, diagnosed using bone mineral density (BMD) measurements. Thus, the growing incidence of osteoporosis is fueling the denosumab market’s growth.

What Segment Types Make Up The Denosumab Market?

The denosumab market covered in this report is segmented –

1) By Drug Classification: Prolia, Xgeva

2) By Type: 60 mg, 120 mg

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Prolia: Prolia 60 Mg Injection, Prolia 1-Year Dosing Schedule, Prolia Osteoporosis Treatment

2) By Xgeva: Xgeva 120 Mg Injection, Xgeva Monthly Dosing Schedule, Xgeva Bone Metastases Management

Which Market Trends Are Creating New Opportunities In The Denosumab Market?

Major companies active in the denosumab market are prioritizing the expansion of global clinical trials and the acceleration of regulatory approvals to fortify their competitive position and broaden treatment accessibility. Clinical trials are human-centric studies that assess the effectiveness and safety of new drugs or therapies. For instance, in May 2023, Boan Biotech, a China-based biopharma company, commenced an international multi-center Phase 3 clinical trial for its denosumab biosimilars BA6101 (Boyoubei) and BA1102, enrolling the initial patient in Europe, the U.S., and Japan. These initiatives follow its 2022 NMPA approval for Boyoubei in postmenopausal women with a high fracture risk. By advancing global clinical development and achieving regulatory momentum, companies enhance their competitiveness in the denosumab market.

Who Are The Key Players Driving Competition In The Denosumab Market?

Major companies operating in the denosumab market are Amgen Inc., Fresenius SE & Co KGaA, Amneal Pharmaceuticals Inc., Dr Reddy’s Laboratories Ltd, Biocon Ltd, Sandoz Group AG, Samsung Bioepis Co Ltd, Celltrion Inc, Organon & Co, Shanghai Henlius Biotech Inc, Teva Pharmaceutical Industries Ltd, Accord Healthcare Ltd, CuraTeQ Biologics Pvt Ltd, AryoGen Pharmed Co, BioXpress Therapeutics AG, Henlius Biotech Co Ltd, JHL Biotech Inc, Oncobiologics Inc, Teva International GmbH (Teva biosimilars unit), Hikma Pharmaceuticals PLC, Gedeon Richter Plc, Accord BioPharma Inc

Read the full denosumab market report here:

https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

How Is The Denosumab Market Distributed Across Key Geographic Regions?

North America was the largest region in the denosumab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Denosumab Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13835&type=smp

Browse Through More Reports Similar to the Global Denosumab Market 2026, By The Business Research Company

Denosumab Market Report 2026

https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

Metformin Market Report 2026

https://www.thebusinessresearchcompany.com/report/metformin-global-market-report

Desmoid Tumors Market Report 2026

https://www.thebusinessresearchcompany.com/report/desmoid-tumors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795